Prolonged high glucose suppresses phorbol 12-myristate 13-acetate and ionomycin-induced interleukin-2 mRNA expression in Jurkat cells

Biochimica et Biophysica Acta - General Subjects

Volumn 1790, Issue 1, 2009, Pages 8-15

  Higai, Koji ^a   Tsukada, Masatoshi ^a   Moriya, Yumiko ^a   Azuma, Yutaro ^a   Matsumoto, Kojiro ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

High concentration of glucose; Inducible cAMP early repressor; Interleukin 2; Nuclear factor of activated T cells

Indexed keywords

GLUCOSE; INTERLEUKIN 2; IONOMYCIN; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; GLUCOSE INTAKE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CYCLIC AMP RESPONSE ELEMENT MODULATOR; GLUCOSE; HUMANS; INTERLEUKIN-2; IONOMYCIN; JURKAT CELLS; NFATC TRANSCRIPTION FACTORS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TETRADECANOYLPHORBOL ACETATE; TIME FACTORS; TRANSCRIPTION FACTOR AP-1;

EID: 57649088916     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2008.10.002     Document Type: Article

References (37)

1. Joshi N., Caputo G.M., Weitekamp M.R., and Karchmer A.W. Infections in patients with diabetes mellitus. N. Engl. J. Med. 341 (1999) 1906-1912
2. Peleg A.Y., Weererethna T., McCarthy J.S., and Davis T.M.E. Common infections in diabetes: pathogenesis, management and relationship to glycaenic control. Diabetes Metab. Res. Rev. 23 (2007) 3-13 (Review)
3. Myśliwska J., Zorena K., Bakowska A., Skuratowicz-Kubica A., and Myśliwski A. Significance of tumor necrosis factor α in patients with long-standing type-I diabetes mellitus. Horm. Metab. Res. 30 (1998) 158-161
4. Pickup J.C., and Crook M.A. Is type II diabetes mellitus a disease of the innate immune system?. Diabetologia 41 (1998) 1241-1248
5. Zozuliñska D., Majchrzak A., Sobieska M., Wiktorowicz K., and Wierusz-Wysocka B. Serum interleukin-8 level is increased in diabetic patients. Diabetologia 42 (1999) 117-118
6. Mooradian A.D., Reed R.L., Meredith K.E., and Scuderi P. Serum levels of tumor necrosis factor and IL-1α and IL-1β in diabetic patients. Diabetes Care 14 (1991) 63-65
7. Ohno Y., Aoki N., and Nishimura A. In vitro production of interleukin-1, interleukin-6, and tumor necrosis factor-α in insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 77 (1993) 1072-1077
8. Shah U., Karch L., Barker L., and Zier K.S. Low interleukin 2 synthesis by type 1 diabetes is regulated at pretranslational level. Clin. Immunol. Immunopathol. 61 (1991) 177-190
9. Kaye W.A., Adri M.N., Soeldner J.S., Rabinowe S.L., Kaldany A., Kahn C.R., Bistrian B., Srikanta S., Ganda O.P., and Eisenbarth G.S. Acquired defect in interleukin-2 production in patients with type I diabetes mellitus. N. Engl. J. Med. 315 (1986) 920-924
10. Chang F.Y., and Shaio M.F. Decreased cell-mediated immunity in patients with non-insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract. 28 (1995) 137-146
11. Northrop J.P., Ho S.N., Chen L., Thomas D.J., Timmerman L.A., Nolan G.P., Admon A., and Crabtree G.R. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature 369 (1994) 497-502 (6480)
12. Wisniewska M.B., Ameyar-Zazoua M., Bakiri L., Kaminska B., Yaniv M., and Weitzman J.B. Dimer composition and promoter context contribute to functional cooperation between AP-1 and NFAT. J. Mol. Biol. 371 (2007) 569-576
13. Johnson B.V., Bert A.G., Ryan G.R., Condina A., and Cockerill P.N. Granulocyte-macrophage colony-stimulating factor enhancer activation requires cooperation between NFAT and AP-1 elements and is associated with extensive nucleosome reorganization. Mol. Cell Biol. 24 (2004) 7914-7930
14. Oum J.H., Han J., Myung H., Hleb M., Sharma S., and Park J. Molecular mechanism of NFAT family proteins for differential regulation of the IL-2 and TNF-α promoters. Mol. Cells 13 (2002) 77-84
15. Rao A., Luo C., and Hogan P.G. Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15 (1997) 707-747 (Review)
16. Macián F., García-Rodríguez C., and Rao A. Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun. EMBO J. 19 (2000) 4783-4795
17. Macián F., López-Rodríguez C., and Rao A. Partners in transcription: NFAT and AP-1. Oncogene 20 (2001) 2476-2489 (Review)
18. Jhun B.S., Lee J.Y., Oh Y.T., Lee J.H., Choe W., Baik H.H., Kim S.S., Yoon K.S., Ha J., and Kang I. Inhibition of AMP-activated protein kinase suppresses IL-2 expression through down-regulation of NF-AT and AP-1 activation in Jurkat T cells. Biochem. Biophys. Res. Commun. 351 (2006) 986-992
19. + T lymphocytes. Blood. 107 (2006) 4841-4848
20. Zachara N.E., and Hart G.W. Cell signaling, the essential role of O-GlcNAc. Biochim. Biophys. Acta 1761 (2006) 599-617 (Review)
21. Huang J.B., Clark A.J., and Petty H.R. The hexosamine biosynthesis pathway negatively regulates IL-2 production by Jurkat T cells. Cell Immunol. 245 (2007) 1-6
22. Beals C.R., Sheridan C.M., Turck C.W., Gardner P., and Crabtree G.R. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 275 5308 (1997) 1930-1934
23. Azuma Y., Miura K., Higai K., and Matsumoto K. Protein O-N-acetylglucosaminylation modulates promoter activities of cyclic AMP response element and activator protein 1 and enhances E-selecting expression on HuH-7 human hepatoma cells. Biol. Pharm. Bull. 30 (2007) 2284-2289
24. Inada A., Yamada Y., Someya Y., Kubota A., Yasuda K., Ihara Y., Kagimoto S., Kuroe A., Tsuda K., and Seino Y. Transcriptional repressors are increased in pancreatic islets of type 2 diabetic rats. Biochem. Biophys. Res. Commun. 253 (1998) 712-718
25. Zhou Y.P., Marlen K., Palma J.F., Schweitzer A., Reilly L., Gregoire F.M., Xu G.G., Blume J.E., and Johnson J.D. Overexpression of repressive cAMP response element modulators in high glucose and fatty acid-treated rat islets. A common mechanism for glucose toxicity and lipotoxicity?. J. Biol. Chem. 278 (2003) 51316-51323
26. Abderrahmani A., Cheviet S., Ferdaoussi M., Coppola T., Waeber G., and Regazzi R. ICER induced by hyperglycemia represses the expression of genes essential for insulin exocytosis. EMBO J. 25 (2006) 977-986
27. Inada A., Hamamoto Y., Tsuura Y., Miyazaki J., Toyokuni S., Ihara Y., Nagai K., Yamada Y., Bonner-Weir S., and Seino Y. Overexpression of inducible cyclic AMP early repressor inhibits transactivation of genes and cell proliferation in pancreatic beta cells. Mol. Cell Biol. 24 (2004) 2831-2841
28. Bodor J., Spetz A.L., Strominger J.L., and Habener J.F. cAMP inducibility of transcriptional repressor ICER in developing and mature human T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 3536-3541
29. Bodor J., and Habener J.F. Role of transcriptional repressor ICER in cyclic AMP-mediated attenuation of cytokine gene expression in human thymocytes. J. Biol. Chem. 273 (1998) 9544-9551
30. Bodor J., Bodorova J., and Gress R.E. Suppression of T cell function: a potential role for transcriptional repressor ICER. J. Leukoc. Biol. 67 (2000) 774-779 (Review)
31. Folco E.J., and Koren G. Degradation of the inducible cAMP early repressor (ICER) by the ubiquitin-proteasome pathway. Biochem. J. 328 (1997) 37-43
32. Yehia G., Schlotter F., Razavi R., Alessandrini A., and Molina C.A. Mitogen-activated protein kinase phosphorylates and targets inducible cAMP early repressor to ubiquitin-mediated destruction. J. Biol. Chem. 276 (2001) 35272-35279
33. Kudlow J.E. Post-translational modification by O-GlcNAc: another way to change protein function. J. Cell. Biochem. 98 (2006) 1062-1075
34. Zhang F., Su K., Yang X., Bowe D.B., Paterson A.J., and Kudlow J.E. O-GlcNAc modification is an endogenous inhibitor of the proteasome. Cell 115 (2003) 715-725
35. Molina C.A., Foulkes N.S., Lalli E., and Sassone-Corsi P. Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell 75 (1993) 875-886
36. Mao D., Warner E.A., Gurwitch S.A., and Dowd D.R. Differential regulation and transcriptional control of immediate early gene expression in forskolin-treated WEHI7.2 thymoma cells. Mol. Endocrinol. 12 (1998) 492-503
37. Krueger D.A., Mao D., Warner E.A., and Dowd D.R. Functional analysis of the mouse ICER (inducible cAMP early repressor) promoter: evidence for a protein that blocks calcium responsiveness of the CAREs (cAMP autoregulatory elements). Mol. Endocrinol. 13 (1999) 1207-1217